Validating the accuracy of mathematical model-based pharmacogenomics dose prediction with real-world data
- PMID: 39832006
- DOI: 10.1007/s00228-025-03805-x
Validating the accuracy of mathematical model-based pharmacogenomics dose prediction with real-world data
Abstract
Objective: The study aims to verify the usage of mathematical modeling in predicting patients' medication doses in association with their genotypes versus real-world data.
Methods: The work relied on collecting, extracting, and using real-world data on dosing and patients' genotypes. Drug metabolizing enzymes, i.e., cytochrome CYP 450, were the focus. A total number of 1914 subjects from 26 studies were considered, and CYP2D6 and CYP2C19 gene polymorphisms were used for the verification.
Results: Results show that the mathematical model was able to predict the reported optimal dosing of the values provided in the considered studies. Predicting patients' optimal doses circumvents trial and error in patients' treatments.
Discussion: The authors discussed the advantages of using a mathematical model in patients' dosing and identified multiple issues that would hinder the usability of raw data in the future, especially in the era of artificial intelligence (AI). The authors recommend that researchers and healthcare professionals use simple descriptive metabolic activity terms for patients and use allele activity scores for drug dosing rather than phenotype/genotype classifications.
Conclusion: The authors verified that a mathematical model could assist in providing data for better-informed decision-making in clinical settings and drug research and development.
Keywords: Allele activity; Artificial intelligence; Cytochrome P450; Dose prediction; Drug metabolism; Genotype; Personalized medicine.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Human Ethics and Consent to Participate Declarations: Not applicable. There was no direct human data collection by the authors. There is no need for either a Consent to Participate Declaration or a Human Ethics Declaration because the authors utilized data that is readily available in the literature. All sources are referenced in the manuscript. Competing Interests: The authors declare no competing interests.
Similar articles
-
Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism: A retrospective study.Medicine (Baltimore). 2021 Mar 19;100(11):e24545. doi: 10.1097/MD.0000000000024545. Medicine (Baltimore). 2021. PMID: 33725937 Free PMC article.
-
Pharmacogenetic prediction of individual variability in drug response based on CYP2D6, CYP2C9 and CYP2C19 genetic polymorphisms.Curr Drug Metab. 2014;15(7):711-8. doi: 10.2174/1389200215666141125121952. Curr Drug Metab. 2014. PMID: 25429673 Review.
-
Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.Eur J Clin Pharmacol. 2009 Apr;65(4):355-63. doi: 10.1007/s00228-008-0573-8. Epub 2008 Nov 1. Eur J Clin Pharmacol. 2009. PMID: 18979093
-
Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.OMICS. 2018 Sep;22(9):575-588. doi: 10.1089/omi.2018.0114. Epub 2018 Sep 11. OMICS. 2018. PMID: 30183544
-
Applications of CYP450 testing in the clinical setting.Mol Diagn Ther. 2013 Jun;17(3):165-84. doi: 10.1007/s40291-013-0028-5. Mol Diagn Ther. 2013. PMID: 23588782 Free PMC article. Review.
References
-
- Nakad Z, Saab Y (2024) Precision dosing for patients on tricyclic antidepressants. Pharmacogenet Genomics 34(4):117–125 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources